Galectin Therapeutics (GALT) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• Galectin Therapeutics (NASDAQ:GALT) is expected to announce its Q2 2025 earnings on August 12th, with analysts predicting a loss of ($0.16) per share.
• The stock recently traded at $3.55, down 1.1%, and has a market capitalization of approximately $224.69 million.
• Bank of America recently increased its stake in Galectin Therapeutics by 101.4% during the fourth quarter, indicating growing institutional interest.

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) is projected to release its Q2 2025 earnings data before the market opens on Tuesday, August 12th. Analysts expect Galectin Therapeutics to post earnings of ($0.16) per share for the quarter.

Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.05. On average, analysts expect Galectin Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Galectin Therapeutics Trading Up 8.1%

NASDAQ:GALT traded up $0.31 during trading hours on Friday, reaching $4.15. 814,354 shares of the company traded hands, compared to its average volume of 310,081. The business's 50-day moving average price is $2.50 and its two-hundred day moving average price is $1.78. The stock has a market capitalization of $262.65 million, a P/E ratio of -5.76 and a beta of 0.82. Galectin Therapeutics has a 1 year low of $0.73 and a 1 year high of $4.41.

Wall Street Analyst Weigh In

GALT has been the subject of several analyst reports. Wall Street Zen raised Galectin Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, June 21st. HC Wainwright began coverage on Galectin Therapeutics in a research note on Tuesday, June 17th. They set a "buy" rating and a $6.00 price target on the stock.

Hedge Funds Weigh In On Galectin Therapeutics

An institutional investor recently raised its position in Galectin Therapeutics stock. Bank of America Corp DE lifted its position in shares of Galectin Therapeutics Inc. (NASDAQ:GALT - Free Report) by 101.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 38,358 shares of the company's stock after purchasing an additional 19,316 shares during the period. Bank of America Corp DE owned about 0.06% of Galectin Therapeutics worth $49,000 at the end of the most recent reporting period. 11.68% of the stock is owned by institutional investors and hedge funds.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.